— Know what they know.
Not Investment Advice

SLS NASDAQ

SELLAS Life Sciences Group, Inc.
1W: +1.6% 1M: +5.0% 3M: +20.5% YTD: +179.8% 1Y: +511.6% 3Y: +1173.7% 5Y: +35.5%
$12.17
+0.83 (+7.32%)
 
Weekly Expected Move ±12.8%
$9 $10 $12 $13 $14
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 45 · $2.5B mcap · 200M float · 3.82% daily turnover · Short 58% of daily vol
Credit Risk of going bust: lower than 68% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), SELLAS Life Sciences Group, Inc. would be worth roughly what it owes.
Total debt $737K against a stock market value of $2.46B.
Distance to default 7.32 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $658K (short-term plus half of long-term), stock volatility 105.3%; Altman Z'' 16.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$78M +303.2% ▲
5Y CAGR: +11.2%
Total Liabilities
$7M -25.0% ▼
5Y CAGR: -16.2%
Shareholders Equity
$71M +648.8% ▲
5Y CAGR: +20.4%
Cash & Investments
$72M +417.7% ▲
5Y CAGR: +15.3%
Total Debt
$1M +0.0% ▲
5Y CAGR: +0.2%
Net Debt
-$71M -450.2% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$21M$17M$3M$14M$72M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$21M$17M$3M$14M$72M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$27K$330K$100K$100K$3M
Total Current Assets$23M$18M$3M$16M$75M
Property, Plant & Equip.$723K$874K$858K$925K$963K
Goodwill & Intangibles$2M$2M$2M$2M$2M
Long-Term Investments$0-$184K$0$0$0
Other Non-Current Assets$594K$399K$275K$466K$257K
Total Non-Current Assets$3M$3M$3M$3M$3M
Total Assets$26M$21M$6M$19M$78M
— Liabilities —
Accounts Payable$2M$3M$6M$4M$3M
Short-Term Debt$198K$0$0$0$544K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$6M$2M$2M$4M
Total Current Liabilities$5M$16M$14M$10M$7M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$336K$4K$0$0$0
Total Non-Current Liabilities$1M$577K$460K$457K$457K
Total Liabilities$6M$16M$14M$10M$7M
— Equity —
Common Stock$2K$2K$3K$7K$15K
Retained Earnings-$139M-$180M-$217M-$248M-$275M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$20M$5M-$8M$9M$71M
Total Liabilities & Equity$26M$21M$6M$19M$78M
— Key Metrics —
Total Debt$808K$945K$906K$1M$1M
Net Debt-$21M-$16M-$2M-$13M-$71M
Total Investments$0-$184K$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms